TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05411263

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Comprehensive transthoracic echocardiography, Doppler echography & Kino-cardiograph (Kino)
Description: As per inclusion criteria, all patients undergo right heart catheterisation to obtain a full profile of invasive hemodynamic measurements, including pulmonary arterial wedge pressure (PAWP), pulmonary artery pressure, right ventricular pressure, right atrial pressure (RAP), superior and/or inferior vena cava pressure, hepatic vein pressure with/without balloon occlusion. Immediately after the invasive hemodynamic exam, a comprehensive 2D, Color Doppler and Doppler echocardiography exam, including a Doppler study of the Vv. hepaticae, V. portae and V. renalis is performed. Based upon logistic feasibility, ballistocardiography and seismocardiography with the completely non-invasive Kino device (HeartKinetics, Waterloo, Belgium) is performed in a subpopulation of patients envisioned to be at least 50 patients.
Study: NCT05084521

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Famotidine 400 mg/50 mL
Description: Administration of a suspension of famotidine, 0.5 mg/kg/12h (with a maximum dose of 80 mg/day, regardless of the patient's weight) during 29 days.
Study: NCT06315985

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental group: Listenning to the Turkish Classical Music to pregnant women diagnosed with preeclampsia
Description: The music to be used in the research will be applied together with midwifery practices and is not a treatment option, tool or treatment option for any disease. Although listening to Classical Turkish music has no effect on treatment and care, it does not have a harmful effect on pregnant women. The participant can withdraw from the study at any time without giving any reason. The Personal Information Form, Perceived Stress Scale, and Pittsburgh Sleep Quality Index (PSQI) will be administered to the pregnant women in both groups participating in the study by face-to-face interviews with the individuals on the first day of their admission to the clinic. At the end of the third day, the Perceived Stress Scale and Pittsburgh Sleep Quality Index (PSQI) scales will be re-administered to both groups.
Study: NCT04967443

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prazosin HCl 2mg
Description: Prazosin HCL 1 X 2 mg capsule.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prazosin HCl 2mg
Description: Prazosin HCL 1 X 2 mg capsule.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prazosin HCl 1 mg
Description: Prazosin HCl 2 X 1 mg capsule.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prazosin HCl 5 mg
Description: Prazosin HCL 1 X 5 mg capsule.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prazosin HCl 5 mg
Description: Prazosin HCL 1 X 5 mg capsule.
Study: NCT04658953

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ultrasound guided infiltration
Description: In the patient in prone position, an infiltration guided by ultrasound will be performed in three puncture points (L3-L4, L4-L5 and L5-S1 levels unilaterally). At each level, 1mL of a mixture consisting of 3mL of Linisol 2% (60mg of lidocaine) and 1mL of Depomedrol 40mg / Lidocaine 10mg is injected.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fluoroscopy guided infiltration
Description: In the patient in prone position, an infiltration guided by fluoroscopy will be performed in three puncture points (L3-L4, L4-L5 and L5-S1 levels unilaterally). At each level, 1mL of a mixture consisting of 3mL of Linisol 2% (60mg of lidocaine) and 1mL of Depomedrol 40mg / Lidocaine 10mg is injected.
Study: NCT06525207

Intervention type: DEVICE
Intervention: Impedance Planimetry, High-definition anorectal manometry and Pelvic Floor Ultrasonography
Description: Global morpho-functional assessment of the anal sphincter complex using Impedance Planimetry, High-definition anorectal manometry and Pelvic Floor Ultrasonography
Study: NCT06153329

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: THDB0206 injection
Description: 0.2 U/kg, single-dose administration, subcutaneous injection 5 cm laterally from the belly button on the left or right side of the abdominal wall

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Humalog®
Description: 0.2 U/kg, single-dose administration, subcutaneous injection 5 cm laterally from the belly button on the left or right side of the abdominal wall

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BC222insulin lispro injection
Description: 0.2 U/kg, single-dose administration, subcutaneous injection 5 cm laterally from the belly button on the left or right side of the abdominal wall
Study: NCT05071469

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Kinesiotaping
Description: KT was applied.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mulligan Mobilization Technique
Description: MMT was applied
Study: NCT05184218

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IGM-6268
Description: Active Comparator

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IGM-6268
Description: Active Comparator

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IGM-6268
Description: Active Comparator

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IGM-6268
Description: Active Comparator

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IGM-6268
Description: Active Comparator

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IGM-6268
Description: Active Comparator

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IGM-6268
Description: Active Comparator

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo Comparator

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo Comparator

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo Comparator

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo Comparator

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo Comparator

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo Comparator

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo Comparator
Study: NCT05975944

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selinexor，Olaparib
Description: Dose level 1: Selinexor 40mg PO QW, Olaparib 150mg PO BID; Dose level 2: Selinexor 60mg PO QW, Olaparib 150mg PO BID; Dose level 3: Selinexor 80mg PO QW, Olaparib 150mg PO BID.
Study: NCT04766398

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: KHK7791
Description: oral administration
Study: NCT06259487

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Coordinated Vaccination
Description: Coordinated Vaccination against Respiratory Syncytial Virus (RSV) and influenza provided by the research team (i.e., during cardiology visits)

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Following recommendations
Description: Guidance on following the standard recommendations for protective vaccinations (i.e., receiving vaccinations at vaccination points).
Study: NCT06312410

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: VIA Family 2.0
Description: Multidisciplinary team based preventive intervention. For details, please see arm/group description.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: VIA Family 2.0
Description: Multidisciplinary team based preventive intervention. For details, please see arm/group description.
Study: NCT04766398

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: oral administration
Study: NCT05845814

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Coformulated favezelimab/pembrolizumab
Description: Coformulated favezelimab/pembrolizumab (800 mg/200 mg) IV infusion
Study: NCT05541627

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: AB-1001 Gene Therapy
Description: One-time intracerebral bilateral injections of AB-1001 (AAVrh10.CAG.hCYP46A1), an adeno-associated viral vector serotype Rh10 containing the human cholesterol 24-hydroxylase gene

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: AB-1001 Gene Therapy
Description: One-time intracerebral bilateral injections of AB-1001 (AAVrh10.CAG.hCYP46A1), an adeno-associated viral vector serotype Rh10 containing the human cholesterol 24-hydroxylase gene
Study: NCT05592327

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Citric acid abutment
Description: The implant surgery will be performed by 3rd year residents of the Postgraduate Program in Periodontology at UIC, supervised by a board-certified periodontist (J.V). Under local anaesthesia, a mid crestal incision will be performed and a full thickness flap will be raised. Implants will be placed following the manufacturer's recommendations. Implant shoulder (IS) will be placed 1 mm subcrestally, and a distance of ≥ 1.5 mm from adjacent natural tooth and ≥ 3 mm between implants will be always respected. Implant stability will be measured with Ostell ISQ. Straight definitive abutments (2 mm height) will be tightened to 25 N respecting the previous randomization procedure. One of the implants will receive an antibacterial- coated abutment (citric acid), while the other implant will receive a non-coated abutment (C). A protector cap will be screwed manually. Implant sites will be sutured with polypropylene 5/0 (Prolene Ethicon, USA) by simple stitches.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Citric acid abutment
Description: The implant surgery will be performed by 3rd year residents of the Postgraduate Program in Periodontology at UIC, supervised by a board-certified periodontist (J.V). Under local anaesthesia, a mid crestal incision will be performed and a full thickness flap will be raised. Implants will be placed following the manufacturer's recommendations. Implant shoulder (IS) will be placed 1 mm subcrestally, and a distance of ≥ 1.5 mm from adjacent natural tooth and ≥ 3 mm between implants will be always respected. Implant stability will be measured with Ostell ISQ. Straight definitive abutments (2 mm height) will be tightened to 25 N respecting the previous randomization procedure. One of the implants will receive an antibacterial- coated abutment (citric acid), while the other implant will receive a non-coated abutment (C). A protector cap will be screwed manually. Implant sites will be sutured with polypropylene 5/0 (Prolene Ethicon, USA) by simple stitches.
Study: NCT06294262

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: TETRALITE
Description: Intramuscular injection of VaxigripTetra with or without LiteVax Adjuvant

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: TETRALITE
Description: Intramuscular injection of VaxigripTetra with or without LiteVax Adjuvant
Study: NCT05845814

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Coformulated vibostolimab/pembrolizumab
Description: Coformulated vibostolimab/pembrolizumab (200 mg/200 mg) IV infusion

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: EV
Description: 1.25 mg/kg IV infusion

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: EV
Description: 1.25 mg/kg IV infusion
Study: NCT05773248

Intervention type: PROCEDURE
Intervention: ERAS protocol
Description: The main concepts of the ERAS protocol compared to standard care included the following aspects: preoperative counselling with a specially trained nurse, restrictive use of preoperative sedation, intraoperative fluid and opioid administration and drain placement, strict antiemetic prophylaxis, early mobilisation, bowel stimulation and removal of any catheters as well as early food intake. Additionally, the ERAS protocol included a 30-day telephone follow-up.
Study: NCT05351671

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RLS-0071 (10 mg/kg intravenously every 8 hours for total of 3 doses)
Description: After challenge with inhaled LPS, subjects will receive IV infusion of RLS-0071 at 10 mg/kg every 8 hours for total of 3 doses.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RLS-0071 (loading dose of 120 mg/kg followed by 40 mg/kg every 8 hours for 2 additional doses)
Description: After challenge with inhaled LPS, subjects will receive IV infusion of RLS-0071 at a loading dose of 120 mg/kg followed by 40 mg/kg every 8 hours for 2 additional doses.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (saline dosed every 8 hours for a total of 3 doses)
Description: After challenge with inhaled LPS, subjects will receive IV infusion of placebo (saline) dosed every 8 hours for a total of 3 doses.
Study: NCT05856643

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SZ011 CAR-NK
Description: In the escalation study, the minimum initial dose was 5.0×10\^6 cells, then increased to 1.0×10\^8, 2.0×10\^8and 5.0×10\^8 cells. The infusion is given every 2 weeks.
Study: NCT06213493

Intervention type: DIAGNOSTIC_TEST
Intervention: measurement of RNAs
Description: RNAs will be measured in heart tissues and in peripheral blood mononuclear cells

Intervention type: DIAGNOSTIC_TEST
Intervention: measurement of RNAs
Description: RNAs will be measured in heart tissues and in peripheral blood mononuclear cells

Intervention type: DIAGNOSTIC_TEST
Intervention: measurement of RNAs
Description: RNAs will be measured in heart tissues and in peripheral blood mononuclear cells

Intervention type: DIAGNOSTIC_TEST
Intervention: measurement of RNAs
Description: RNAs will be measured in heart tissues and in peripheral blood mononuclear cells
Study: NCT05845814

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: EV
Description: 1.25 mg/kg IV infusion

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Pembrolizumab
Description: 200 mg IV infusion
Study: NCT04642287

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Calcipotriol Only Product in Cutaneous Dose Form
Description: Calcipotriene is a form of vitamin D. It works by inducing thymic stromal lymphopoietin cytokine expression in the skin.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vaseline
Description: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topical 5FU
Description: 5-FU is a chemotherapy that causes the death of proliferating tumor cells. Topical preparation of this drug is being used.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Topical 5FU
Description: 5-FU is a chemotherapy that causes the death of proliferating tumor cells. Topical preparation of this drug is being used.
Study: NCT05786209

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Whole-body Balm
Description: Balm will be applied to cover newborn's entire body (while avoiding the mouth, eyes, diaper area, and scalp), and gently massaged onto the skin until the balm is fully absorbed.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Wash and Shampoo
Description: Wash and shampoo will be used to cleanse newborn baby using an in tub bathing method.
Study: NCT05079529

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: β-1,3/1,6-D-Glucan From Mycelia Extract of Indonesia's Ganoderma Lucidum Group
Description: Takes β-1,3/1,6-D-Glucan capsule 3 times daily for 90 days
Study: NCT06500611

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sensory Integration and Vestibular Exercise with Routine Physical Therapy
Description: 1. Stand with feet hip-width apart 5 rep~2. Sit in chair without backrest 5 rep~1.Stand with feet hip -width apart 5 rep~2.Sit to stand sit on chair without backrest and perform sit to stand repeatedly 5 rep~1.Tandem Walk one foot directly in front of the other.2 sets 5 steps forward and backward~2.Patientwalk forward cross an obstacle, continue walk. Walk Lateral Walk Backward 2 sets~1. Stand and slowly move head side to side and up down 10 repetition~2. Fix gaze and move head side to side or up and down 10 repetitions~1. Stand on one leg for 10 seconds hold on. Repeat 5 times on each leg.~2. Stand and rotate body to right and left 10 rotations~1. Walk on straight line , zigzag pattern, walk while looking your shoulder 5 rep~2. Sit and swing your legs back and forth 5rep~3. Play catch in standing. 2 sets 5-8 catches.~Static stretching 30 sec hold 5 times

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Vestibular Exercise with Routine Physical Therapy
Description: Vestibular exercise~1. Stand with feet hip -width apart and slowly move head side to side and up down.10 repetitions for each direction.~2 .Fix your gaze on object while moving your head side to side or up and down. 10 repetitions for each movement.~1.Patient will stand on one leg for 10 second. Hold onto a stable support if needed. 5 times on each leg.~2. Stand with feet hip-width apart and rotate body to the right and left. 10 rotations in each direction.~1. Walk on a straight line or in a zigzag pattern or walk while looking over your shoulder. (5 rep)~2. Sit on a stable chair and swing your legs back and forth, similar to a pendulum. (5rep)~3. Catch and Throw play catch with a partner while standing. 2 sets of 5-8 catches.~Routine Physical Therapu Static stretching exercises for 30 sec hold with 30 sec rest. 5 times for each muscle group
Study: NCT06549283

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Nasal intermittent positive pressure ventilation (NIPPV) via binasal cannula during neonatal intubation
Description: Researchers applied NIPPV treatment using binasal cannulas through a mechanical ventilator during intubation.
Study: NCT05079529

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Group
Description: Takes placebo capsule 3 times daily for 90 days
Study: NCT05232461

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PrimeC-ER 748 mg
Description: PrimeC-ER is an extended release formulation of a fixed dose combination of ciprofloxacin and celecoxib

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PrimeC-ER 748 mg
Description: PrimeC-ER is an extended release formulation of a fixed dose combination of ciprofloxacin and celecoxib

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ciprofloxacin 750 MG
Description: Ciprofloxacin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Celecoxib 200mg
Description: Celecoxib
Study: NCT05499949

Intervention type: DIAGNOSTIC_TEST
Intervention: NASH screening
Description: Evaluate liver steatosis and elasticity using transient elastography in the FONS group

Intervention type: DIAGNOSTIC_TEST
Intervention: Cardiac dysfunction screening
Description: Evaluate cardiac dysfunction in 60 patients from the FONS group with transthoracic echocardiography

Intervention type: DIAGNOSTIC_TEST
Intervention: Liver biopsy
Description: For participants from the FONS group with an elevated liver fibrosis measurement (≥F2) with TE, a laparoscopic liver biopsy will be performed during the bariatric procedure.
Study: NCT05272748

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Conventional Exercise + Core Stabilization Exercise
Description: Before and after the treatment, patients' pain, postural control (static and dynamic balance), functional level and fear of falling will be evaluated. In addition to the exercises in the conventional exercise group, patients will perform pelvic tilt, lateral bridge, single leg bridge, plank, extremity exercises in the crawling position, abdominal crunch, oblique crunch, dead bug, superman exercise. Exercises will be applied 3 times a week.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Conventional Exercise
Description: Before and after the treatment, patients' pain, postural control (static and dynamic balance), functional level and fear of falling will be evaluated. Terminal knee extension, straight leg raise, heel slide, adductor isometric, bridge, mini squat, heel raise, lunge, range of motion and stretching exercises for lower extremities will be performed by the patients. Exercises will be applied 3 times a week.
Study: NCT04954027

Intervention type: BEHAVIORAL
Intervention: Questionnaires
Description: 5 visits are planned during the study :~* the inclusion visit : during this visit the patient's non-opposition is obtained and then the patient answer to self-administered questionnaires online~* 4 telephone interviews for follow-up by investigator
Study: NCT06294262

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TETRALITE
Description: Intramuscular injection of VaxigripTetra with or without LiteVax Adjuvant

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TETRALITE
Description: Intramuscular injection of VaxigripTetra with or without LiteVax Adjuvant

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TETRALITE
Description: Intramuscular injection of VaxigripTetra with or without LiteVax Adjuvant

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TETRALITE
Description: Intramuscular injection of VaxigripTetra with or without LiteVax Adjuvant
Study: NCT05570708

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MDMA, LSD, psilocybin
Description: * MDMA per os (2 x 100mg) in a group setting~* LSD per os (75 and 150 mcg) in a 1:1 setting~* Psilocybin per os (15 mg and 25 mg) in a group setting~* Three study days are without drug administration: Participants experience the role of the therapist in a 1:1 setting
Study: NCT04655807

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-64304500
Description: JNJ-64304500 will be administered as SC injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-64304500
Description: JNJ-64304500 will be administered as SC injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching placebo will be administered as SC injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching placebo will be administered as SC injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adalimumab
Description: Adalimumab will be administered as SOC biological therapy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ustekinumab
Description: Ustekinumab will be administered as SOC biological therapy.
Study: NCT06071663

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Single and two visits pulpectomy
Description: Comparison of clinical and radiographic outcome of Single and two visits pulpectomy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Single and two visits pulpectomy
Description: Comparison of clinical and radiographic outcome of Single and two visits pulpectomy